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Albumin KeÂnitra is a new type of genetic variant of human
serum albumin that has been found in two members of a
family of Sephardic Jews from KeÂnitra (Morocco). The
slow-migrating variant and the normal protein were isolated
by anion-exchange chromatography and, after treatment
with CNBr, the digests were analyzed by two-dimensional
electrophoresis in a polyacrylamide gel. The CNBr peptides
of the variant were purified by reverse-phase high per-
formance liquid chromatography and submitted to sequence
analysis. Albumin KeÂnitra is peculiar because it has an
elongated polypeptide chain, 601 residues instead of 585,
and its sequence is modified beginning from residue 575.
DNA structural studies showed that the variant is caused by
a single-base insertion, an adenine at nucleotide position
15 970 in the genomic sequence, which leads to a frame-
shift with the subsequent translation to the first termination
codon of exon 15. Mass spectrometric analyses revealed
that the four additional cysteine residues of the variant form
two new S±S bridges and showed that albumin KeÂnitra is
partially O-glycosylated by a monosialylated HexHexNAc
structure. This oligosaccharide chain has been located to
Thr596 by amino-acid sequence analysis of the tryptic
fragment 592±597.
Keywords: human serum albumin; extended genetic variant;
O-glycosylation; disulfide bridges; frameshift.
Bisalbuminemia is a rare inherited trait characterized by the
presence of a circulating variant of human serum albumin
(HSA) that is usually detected during screening of plasma
proteins either in routine clinical electrophoresis or in
systematic genetic surveys [1]. The occurrence of two
albumin bands in electrophoresis, representing normal and
variant protein, has been observed with a frequency of
0.0003±0.0010 in the average population, but is not clearly
associated with disease [1]. The only reported cases of
clinical relevance are the Arg218!His and Arg218!Pro
mutations that have been found to be responsible for
familial dysalbuminemic hyperthyroxinemia [2±4], and
Leu66!Pro, which is responsible for familial dysalbumin-
emic hypertriiodothyroninemia [5].
In the last two decades, several genetic variants of HSA
have been studied in different laboratories in an attempt to
correlate the changes in the protein sequence with the
functional properties and stability of the molecule. These
studies have allowed the characterization by protein and/or
DNA sequence analysis of more than 60 different genetic
mutations [6,7] (see the continuously updated website at
http://www.albumin.org) and have provided a unique
insight into albumin's ligand binding sites [6,8,9]. Nearly
all the known albumin mutations occur on the molecular
surface and most of them are clustered in three regions: the
propeptide and N-terminal region, and the C-terminal parts
of subdomains IIB and IIIB [10]. The vast majority of them
reflects the existence of single-base changes in the struc-
tural gene, and the recurring alloalbumins are associated
with mutations in hypermutable CpG dinucleotides [11,12].
Albumin synthesis is governed by a single copy gene
codominantly expressed why heterozygous subjects usually
show the presence of the normal and the variant proteins in
a 1 : 1 ratio. However, four different genetic events have
been reported to give rise to low-concentration chain
termination mutants. These include: (a) single nucleotide
deletions and subsequent frameshifts in albumins Catania
[13,14] and Bazzano [15]; (b) a 25-bp deletion that results
in the skipping of exon 14 in albumin Venezia [14,16]; (c) a
GT to CT 5 0 splice mutation in intron 13 of albumin Rugby
Park [17]; and (d) the introduction of an alternative 3 0
splice site in intron 13 of albumin Banks Peninsula [7].
Normal HSA is not glycosylated but there are three point
mutations that give rise to the canonical Asn-Xaa-Thr/Ser
tripeptide acceptor sequence for N-glycosylation. In every
case, the mutated sequences turned out to be N-glycosy-
lated: Asp63!Asn [18], Ala320!Thr [19] and Asp494!Asn
[10,20].
In the present work we have identified, using both
protein and DNA sequence analysis, the molecular changes
of a new type of slow-migrating alloalbumin found in a
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66-year-old patient and her sister, Sephardic Jews from
KeÂnitra (Morocco) [21]. This variant, which represents
about 15% of the total plasma albumin, is caused by a
single-base insertion, an adenine at nucleotide position
15 970 in the genomic sequence [22], which leads to a
frameshift and subsequent translation to the first termina-
tion codon of exon 15. This results in an elongated
polypeptide chain, 601 residues instead of 585, with a
modified sequence from residue 575. Mass spectrometric
analyses reveal that the abnormal C-terminal sequence of
this mutant contains two additional disulfide bridges and an
O-linked oligosaccharide chain. Thus, albumin KeÂnitra
represents the first example of an extended and
O-glycosylated circulating mutant of HSA.
M A T E R I A L S A N D M E T H O D S
Albumin purification
The serum sample (2 mL) was desalted through a PD10
column, freeze dried, dissolved in 500 mL of 20 mm
sodium acetate, pH 5.2 (buffer A), and injected on a
preparative DEAE-5PW column (21.5  150 mm;
Bio-Rad). Elution was achieved using a 40-min linear pH
gradient from 100% buffer A to 100% buffer B (20 mm
sodium acetate, pH 4.5) at a flow rate of 5 mL´min21 [18].
Peaks were analyzed by polyacrylamide gel electrophoresis
at pH 8.3 and the fractions containing the variant and the
normal albumins were pooled and lyophilized.
Protein structural studies
After reduction and carboxymethylation, normal and
variant albumins were cleaved with CNBr and the digests
were compared by two-dimensional electrophoresis to
identify the fragment containing the substitution site. The
first dimension, isoelectric-focusing, was performed on
laboratory-made polyacrylamide gels cast on GelBond,
dried and rehydrated to the original thickness of 0.5 mm
with a solution containing 8 m urea and carrier ampholytes
in the pH range 2.5±8.0 [13]. After isoelectric focusing, the
gel strips were equilibrated with SDS and placed on top of
vertical 17% polyacrylamide SDS gels, and the second
dimension was carried out using a Mini PROTEAN II cell
(Bio-Rad).
The major part of the CNBr digests were then analysed
by RP-HPLC on a Vydac C18 column (4.6  250 mm; The
Separation Group). The lyophilized digests were dissolved
in 50 mL of 70% formic acid 1 150 mL of 0.1% aqueous
trifluoroacetic acid (solvent A), and 100 mL (corresponding
to about 10 nmol) were injected onto the Vydac C18
column equilibrated with solvent A. Peptides were eluted at
a flow rate of 1 mL´min21 with the equilibration buffer for
8 min followed by a two-step linear gradient: from 0 to
30% of solvent B (0.1% trifluoroacetic acid in acetonitrile/
2-propanol, 2 : 1, v/v) in 3 min and from 30 to 50% of
solvent B in 60 min.
Amino-acid sequence analysis of the two purified variant
peptides were performed by an Applied Biosystems model
477 A (Aarhus) or by a Hewlett-Packard model G 1000 A
sequencer (Centro Grandi Strumenti, UniversitaÁ di Pavia).
The lyophilized CB7M was dissolved in 0.1 m NH4HCO3
and digested with trypsin (Roche) for 3 h at 37 8C using an
enzyme/substrate ratio of 1 : 50. The reaction was termi-
nated by addition of trifluoroacetic acid and the digest was
directly injected onto the Vydac C18 column equilibrated
in 0.1% aqueous trifluoroacetic acid (solvent A). Tryptic
peptides were eluted with a 60-min linear gradient from 0 to
30% of solvent B (0.1% trifluoroacetic acid in acetonitrile)
at a flow rate of 1 mL´min21 and submitted to amino-acid
sequence analysis.
DNA structural studies
Genomic DNA was extracted from whole blood by using
the lysis buffer and proteinase K digestion protocol [23]. A
339-bp fragment containing exon 14 of the albumin gene
was amplified by PCR using primers A27A and A28A [23].
PCR was performed in a 25-mL reaction volume using
Ready to Go Beads (Amersham Pharmacia Biotech) with a
final MgCl2 concentration of 1.5 mm. Conditions for
amplification included an initial DNA denaturation at
94 8C for 3 min, followed by 35 cycles of denaturation at
94 8C for 30 s, primer annealing at 64 8C for 30 s and
elongation at 72 8C for 30 s. Finally an extension at 72 8C
was performed for 3 min. Single strand conformation
polymorphism (SSCP) and heteroduplex analysis was per-
formed either on the whole PCR product or on restriction
fragments generated by digestion with AluI (Amersham
Pharmacia Biotech). To test for SSCP and heteroduplexes,
PCR products and their restriction digests were denatured at
95 8C for 3 min and placed on ice before the electro-
phoretic separation. Samples were then loaded on hori-
zontal ultra-fine gels (gel thickness 0.3 mm) composed of
15% acrylamide (acrylamide/piperazine diacrylamide
85 : 1) with 8% glycerol in 120 mm Tris/formate buffer,
pH 9.0. The electrodes consisted of paper wicks soaked in
1.04 m Tris/borate, pH 9.0, and the gels were run in a
Pharmacia Multiphore II apparatus at 6 8C for 90 min at 0.8
Watt´cm21 [24]. Bands were visualized by silver staining.
In order to confirm the mutation by PCR, a restriction
site for the mutated allele was introduced using a modified
primer 5 0-GTCTTTGTGTTCAGGGTAAATTA-3 0 (A31M;
the modified nucleotides are underlined). A31M was used
with primer 5 0-AGCATCTCAGGTAACTATAT-3 0 (A32M)
to amplify a 92-bp PCR fragment. The thermocycle profile
was as follows: initial DNA denaturation at 94 8C for
3 min, followed by 35 cycles of 30 s at 94 8C, 30 s at 52 8C
and 20 s at 72 8C. The PCR products were digested with
Tru9I (Roche) according to the manufacturer instructions
and the restriction digests were analyzed by electrophoresis
in nondenaturing 15% polyacrylamide gels in 0.09 m
Tris/borate, 2 mm EDTA, pH 8.0 in a Mini PROTEAN II
cell (Bio-Rad) followed by silver staining.
Reduction and alkylation of cysteine residues
An aliquot of albumin KeÂnitra was reduced in 0.25 m
Tris/HCl, pH 8.5, containing 1.25 mm EDTA and 6 m
guanidinium chloride with a 10 : 1 molar excess of
dithiothreitol over the SH groups, for 2 h at 37 8C under
nitrogen atmosphere. Alkylation of cysteine residues on the
native or reduced protein was carried out in the denaturing
buffer with 10 : 1 molar excess of iodoacetamide over the
total SH groups for 30 min at room temperature, in the dark
under nitrogen atmosphere. Alkylated protein samples were
desalted by RP-HPLC on a Vydac C4 column
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(25  0.46 cm, 5 mm) using 0.1% trifluoroacetic acid
(solvent A) and 0.07% trifluoroacetic acid in 95%
acetonitrile (solvent B) by means of a linear gradient
from 20 to 95% solvent B in 10 min. The fractions were
manually collected and directly analysed by electrospray
mass spectrometry (ESMS).
Isolation and chemical derivatization of oligosaccharide
chains
O-Linked oligosaccharides were released from the glyco-
sylated CB7M fraction by reductive elimination carried out
in 50 mm NaOH containing 1 m sodium borohydride at
45 8C for 18 h [25]. The oligosaccharides were permethyl-
ated with methyl iodide in dimethylsulfoxide using the
sodium hydroxide procedure to increase the sensitivity of
MALDI MS analysis [26]. Derivatized samples were
diluted with water, extracted in chloroform and dried in a
Speed-Vac centrifuge.
Mass spectrometric analyses
Intact proteins or individual peptide fractions from CNBr
digestion of albumin KeÂnitra were submitted to ESMS
analysis using either a VG Bio-Q triple quadrupole
(Micromass) or an API 100 single quadrupole (PerkinElmer
Applied Biosystems Inc) mass spectrometer. Samples were
dissolved in 1% acetic acid in 50% acetonitrile and injected
into the mass spectrometer at a flow rate of 5 mL´min21.
The quadrupole was scanned from m/z 600±1800 at 10 s
per scan and the spectra were acquired using masslynx or
the biomultiviewer software. Calibration was performed
by a separate injection of myoglobin (m 16951.5 Da). All
mass values are reported as average masses.
MALDI MS analysis of oligosaccharides was carried out
using a Voyager DE mass spectrometer (PerSeptive
Biosystems). The mass range was calibrated with the
molecular ions of two peptides, WMDF-NH2 at m/z 598.7
and angiotensin I at 1297.5 as internal standards. Samples
were dissolved in methanol and a 1-mL aliquot was mixed
with 1 mL of a solution of 2,5-dihydroxybenzoic acid
(10 mg´mL21) in acetonitrile/0.2% trifluoroacetic acid
2 : 1 (v/v), applied to a sample slide and allowed to
air-dry. Raw data were analysed by using a computer
software provided by the manufacturer and are reported as
average masses.
R E S U L T S A N D D I S C U S S I O N
Protein structural studies
The variant protein and its normal counterpart were isolated
from the patient's serum by anion-exchange chromato-
graphy on a DEAE-5PW column. As expected on the basis
of the electrophoretic mobility on cellulose acetate where it
comigrates with a1 antitrypsin [21], the variant peak eluted
at a pH value of about 0.2 units higher than that of the
corresponding normal albumin (Fig. 1). The ratio between
the quantities of the two albumins obtained, 0.175, is in
Fig. 1. HPLC elution profile on a DEAE-5PW column of the KeÂnitra serum. The serum sample (2 mL) was desalted by a PD10 column, freeze
dried, dissolved in 500 mL of 20 mm sodium acetate, pH 5.2 (buffer A) and injected on the DEAE-5PW column equilibrated with the same buffer.
Elution was achieved using a 40-min pH-linear gradient (dashed line) from 100% buffer A to 100% buffer B (20 mm sodium acetate, pH 4.5) at a
flow rate of 5 mL´min21.
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keeping with the value determined by scanning the two
albumin bands on cellulose acetate electrophoresis [21]. In
order to localize the mutation, KeÂnitra and normal albumins
were reduced, carboxymethylated, cleaved with cyanogen
bromide and examined by two-dimensional electrophoresis
in a polyacrylamide gel (Fig. 2). This analysis showed that
all the CNBr fragments from the two albumins were
identical with the exception of fragment CB7 in the variant,
which gave rise to three spots with values of isoelectric
point (pI) in the pH range 4.55±4.65, while the correspond-
ing normal peptide migrated as a single spot with a pI value
of 4.3. The finding of multiple spots suggested the presence
of different forms of the abnormal fragment. In addition,
their slower mobilities in the second dimension indicated a
significant increase in the molecular mass (Fig. 2). The
CNBr mixtures from the two proteins were resolved by
RP-HPLC on a Vydac C18 column (Fig. 3) and all the
fractions were identified by N-terminal sequence analysis.
In the profile of albumin KeÂnitra, fragment CB7M is clearly
eluted earlier than normal and appears as a broad and
heterogeneous peak. In addition, a new and very hydro-
philic peak, that we have labelled CB8M, shows up. Both
CB7M and CB8M were directly submitted to amino-acid
sequence determination.
Fragment CB7M gave a single 49 amino-acid sequence:
DDFAAFVEKCCKADDKETCFAEEGKKTCCCKSSCLR-
LITSHLKASQPTM, which is completely different from
that of the normal protein following Thr575 (underlined).
Sequence analysis showed that the hydrophilic peak,
CB8M, consists of a new basic tetrapeptide, RIRE. This
additional fragment must be positioned at the C-terminus of
the bisalbumin molecule because of the presence of a
methionine at the C-terminal position of CB7M.
The results obtained so far indicate that albumin KeÂnitra
has an elongated polypeptide chain, 601 residues instead of
585, completely variant from residue 575 to the C-terminal
end: TCCCKSSCLRLITSHLKASQPTMRIRE. The
C-terminal sequence of the variant is reported in Fig. 4,
together with the known nucleotide sequence of the
corresponding region of the structural gene of HSA [22],
starting from residue 572, which corresponds to the first
codon of exon 14. This exon, which is 68 bp long and
normally only partially translated, specifies the last 14
residues of HSA and contains the terminator codon (TAA)
(Fig. 4, upper part). The amino-acid sequence we have
found for albumin KeÂnitra can be accounted for by a single-
base insertion: an adenine at nucleotide position 15 970,
which leads to a frameshift with the subsequent translation
of all of exon 14 and until the first termination codon of
exon 15 (163 bp), which normally does not code for the
protein but is conserved in the mature mRNA [22]. The
seven C-terminal residues of the variant correspond to
the first seven codons of this exon, while the eighth and the
ninth codons specify for arginine and lysine, respectively,
and the tenth is a stop codon (TGA) (Fig. 4, lower part). We
did not find evidence for the presence in the circulating
variant of the C-terminal dipeptide Arg-Lys. These two
amino acids have probably been removed by one of the
basic carboxypeptidases, carboxypeptidase B or carboxy-
peptidase N, which are active in the plasma compartment
[27]. This phenomenon has previously been observed in
another C-terminally modified but shortened mutant of
HSA, albumin Venezia, which has the same seven
C-terminal residues as albumin KeÂnitra. In that case, there
was a 25-bp deletion resulting in the skipping of exon 14
and in a continued translation of exon 15 until the
terminator codon was encountered [14,16]. However, in
albumin Venezia the digestion was only partial, as about
20% of the circulating variant retained the arginine residue
at its C-terminal end.
Fig. 2. Two-dimensional electrophoresis of the CNBr fragments from carboxymethylated normal (A) and KeÂnitra (B) albumins. The first
dimension (horizontal) is isoelectric focusing in the presence of 8 m urea in the pH range 2.5±8.0. The second dimension (vertical) was carried out
as SDS/PAGE on 17% polyacrylamide gels which were stained with Coomassie Brilliant Blue. Fragments CB2 and CB8M were not identified,
probably owing to their high solubility and low affinity for the dye. Microheterogeneity, mostly in the case of larger fragments, is probably due to
partial cleavage, oxidation of unreacted cysteines or to deamidation. CB7M denotes the variant peptide of albumin KeÂnitra.
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DNA structural studies
In order to check for the adenine insertion at nucleotide
position 15 970, genomic DNA was extracted from whole
blood and a 339-bp fragment, containing exon 14 of the
albumin gene, was amplified by PCR using primers A27A
and A28A [23] and submitted to SSCP and heteroduplex
analysis. The PCR product was also digested with AluI,
which gave rise to three fragments of 94, 104, 141 bp,
respectively. Figure 5 shows the electrophoretic patterns
obtained for the native and denatured samples from the
patient and two normal controls. A clear heteroduplex band
Fig. 3. RP-HPLC elution profile on a Vydac C18 column of the CNBr fragments from carboxymethylated KeÂnitra (dotted line) and normal
(full line) albumins. The lyophilized CNBr digests were dissolved in 50 mL of 70% formic acid 1 150 mL of 0.1% aqueous trifluoroacetic acid
(solvent A), and 100 mL (corresponding to about 10 nmol) were injected on the Vydac C18 column equilibrated with solvent A. Peptides were
eluted at a flow rate of 1 mL´min21 using the gradient indicated by the dashed line. Solvent B was 0.1% trifluoroacetic acid in acetonitrile/
2-propanol 2 : 1, v/v. CB7M and CB8M denote the two variant peptides resulting from the mutation of albumin KeÂnitra.
Fig. 4. Nucleotide and amino-acid sequences of the C±terminal regions of normal albumin and albumin KeÂnitra. The additional adenine at
nucleotide position 15 970 in the genomic sequence of albumin KeÂnitra is indicated in bold. The O-glycosylated Thr596 is marked by an asterisk.
The two arrowheads mark the cleavage sites for the two basic C-terminal residues, which are absent in the circulating protein.
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is present in the amplified abnormal exon 14 (lanes 1 and
4), as well as in the 104-bp AluI fragment (lanes 7 and 10).
This result confirms that the mutation is located within the
region 15 886±15 989 of exon 14. Then, the variant and
control DNA were amplified using primer A32M and the
modified primer A31M, which introduces at the point of
the presumed insertion a restriction site for Tru9I in the
mutated allele. The PCR products, encompassing nucleo-
tides 15 947±16 038 of the HSA gene, were digested with
the enzyme and the restriction fragments analysed by
nondenaturing 15% PAGE. The wild-type gave rise to
two fragments of 70 and 22 bp because of the presence
of a restriction site for Tru9I at nucleotide position
16 014, while in the mutant the 71-bp fragment was
further cleaved into two fragments of 48 and 23 bp, thus
confirming the adenine insertion in nucleotide position
15 970 (Fig. 6).
Mass spectrometric analysis of the intact variant
The status of the four additional cysteine residues present in
the C-terminal region of albumin KeÂnitra was investigated
by mass spectrometric analysis. The variant protein was
either alkylated with iodoacetamide without any reduction
step or submitted to dithiothreitol treatment followed by
carboxyamidomethylation under denaturing conditions.
Both the alkylated and the reduced and carboxyamido-
methylated samples were desalted by RP-HPLC on a Vydac
C4 column and directly analysed by ESMS. The results are
summarized in Table 1. When the reduction step was
omitted, the ES spectra showed the presence of two main
components whose molecular masses were measured as
69199.2 ^ 4.7 Da and 68538.9 ^ 5.6 Da, respectively.
The lower mass value is in good agreement with that
expected on the basis of the new 601 amino-acid sequence
of the variant albumin with a single alkylated cysteine
residue (68544.1 Da), confirming the removal of the
C-terminal Arg-Lys dipeptide. This result demonstrates
that the four extra cysteine residues present in the
C-terminal region of the variant are all involved in S-S
bridges. The obligatory pairings of the two new disulfide
bonds are Cys576±Cys578 and Cys577±582, because three
cysteine residues are contiguous in the primary structure.
The only cysteine alkylated by iodoacetamide should then
be Cys34, the single unpaired cysteine occurring in normal
HSA. The second component exhibited a mass increase of
about 660±670 Da as compared to the variant albumin, an
increment which we could not account for at this stage of
the investigation.
Two molecular species were also detected in the ES
spectra of the reduced and alkylated abnormal albumin,
showing molecular masses of 71416.5 ^ 4.3 Da and
70745.9 ^ 4.8 Da, respectively. The lower mass value
corresponds to the modified protein in which all the 39
cysteine residues have been alkylated by iodoacetamide,
confirming the oxidation state of the new four cysteines.
The second species showed again a mass increase of
660±670 Da, as previously determined for the alkylated
variant. Because the mass difference between the two
albumins is conserved even after reduction and alkylation
under denaturing conditions, these results suggest that the
variant sample consists of two forms which differ by a still
unknown covalent modification. The ratio between these
two forms can be estimated as < 1 : 1.
Fig. 5. Heteroduplex and SSCP analysis of exon 14. DNA from
KeÂnitra and two controls were amplified with primers A27A and A28A
and the PCR fragments were electrophoresed onto a nondenaturing
polyacrylamide gel (lanes 1, 2, and 3, respectively). The same samples
were denatured and cooled before loading (lanes 4, 5, and 6). The same
PCR fragments were analyzed after digestion with AluI (lanes 7, 8, and
9) and after digestion with AluI with prior denaturation (lanes 10, 11,
and 12). The open arrowhead denotes the abnormal heteroduplex in
lanes 1 and 4. The closed arrowhead indicates the single abnormal
heteroduplex after digestion with AluI in lanes 7 and 10.
Table 1. Electrospray mass analysis of the intact variant. CAM,
carboxyamidomethylated; REDCAM, reduced and carboxyamido-
methylated.
Molecular mass (Da)
Measured Theoretical
CAM albumin KeÁnitra 68 538.9 ^ 5.6 68 544.1
69 199.2 ^ 4.7
REDCAM albumin KeÁnitra 70 745.9 ^ 4.8 70 752.6
71 416.5 ^ 4.3
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Mass spectrometric characterization of the CNBr
peptides from albumin KeÂ nitra
The exact molecular masses of the individual CNBr
peptides, fractionated by RP-HPLC (Fig. 3), were deter-
mined by direct ESMS analysis. All but one of the peptides
analysed by ESMS displayed the expected molecular mass,
including the newly detected CB8M. However, mass
spectral investigation of the broad chromatographic peak
corresponding to the CB7M fragment showed the presence
of two components, whose molecular masses were
measured as 5779.6 ^ 0.4 Da and 6438.8 ^ 0.8 Da. The
lower mass value perfectly matched that expected on the
basis of the new C-terminal sequence of albumin KeÂnitra.
The second species showed a molecular mass about
659.2 Da higher than that of the variant CB7M. This
mass difference corresponds to the entire mass difference
observed in the analysis of the intact variant, thus
confirming that the covalent modification is confined
within this fragment.
The variant CB7M was then deglycosylated by reductive
elimination following the procedure reported by Carlson
[25]. The putative oligosaccharides released from the
polypeptide chain were permethylated and submitted to
MALDI MS analysis. The resulting MALDI spectra
showed the occurrence of a mass signal at m/z 895,
corresponding to a monosialylated HexHexNAc structure.
This finding demonstrates that albumin KeÂnitra exists as
two molecular species differing in the presence of
O-glycosylation at level of CB7M.
Localization of the O-glycosylation site
As the mutated C-terminal region of the variant contains
four serine and three threonine residues, in order to localize
the O-glycosylation site the variant CB7M was cleaved
with trypsin and the fragments were resolved by RP-HPLC
(data not shown). All the expected peptides were identified
and their amino-acid sequences were in total agreement
with the results obtained on the whole CB7M. The only
exception was the C-terminal fragment (residues 592±597),
that gave rise to four different peaks, due to partial
glycosylation and to the homoserine/homoserine lactone
equilibrium. Amino-acid sequence analysis of these peaks
showed that in two of the fractions the threonine residue at
position 596 was clearly detectable, while a blank was
found at the same position in the other two species, thus
indicating that the oligosaccharide chain is O-linked to
Thr596.
The specificities of the UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferases which link the carbo-
hydrate GalNAc to the side chain of certain serine and
threonine residues in mucin type glycoproteins are not yet
defined, but there is a widely used program that predicts the
O-glycosylation sites in mammalian proteins on the basis of
sequence context, secondary structure and surface acces-
sibility [28]. Use of this program on the C-terminal region
of albumin KeÂnitra shows that only Thr596, among the
possible sites, has a glycosylation potential close to,
although lower than, the threshold value. This finding is
in full accordance with the results of the amino-acid
sequencing of the variant CB7M tryptic fragments. Thr596
is adjacent to a Pro residue, which has been reported to
favor oligosaccharide addition to threonine residues [29].
The partial glycosylation of this residue indicates that it
is easily accessible to the UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferase and therefore reflects
the high exposure to the solvent of the C-terminal region of
the variant.
C O N C L U S I O N S
Albumin KeÂnitra is a new type of genetic variant of HSA
that arises from the insertion of an adenine residue at
nucleotide position 15 970 in the structural gene. This
mutation causes a shift of the reading frame and the
translation of all of exon 14 and part of exon 15, which
normally does not code for protein [22], until the first
Fig. 6. Artificial insertion restriction site
analysis of exon 14 in polyacrylamide gel.
Exon 14 of the albumin gene was amplified
by PCR using a mismatch primer
5 0-GTCTTTGTGTTCAGGGTAAATTA-3 0
(A31M), which introduces an additional
restriction site for Tru9I in the mutated allele.
A31M was used with primer
5 0-AGCATCTCAGGTAACTATAT-3 0 (A32M) to
amplify a 93-bp PCR fragment, which was then
digested with Tru9I. PCR products from KeÂnitra
and two controls were electrophoresed onto a
nondenaturing polyacrylamide gel before (lanes 2,
3, and 4, respectively) and after digestion with
Tru9I (lanes 5, 6, and 7, respectively). Lane 1:
molecular mass markers. The asterisk marks the
48-bp fragment produced by the cleavage at the
artificial restriction site.
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termination codon. This is in full accord with the primary
structure of the protein, which has an elongated polypeptide
chain, 601 residues instead of 585, and is completely
different from the normal molecule starting from residue
575. In addition the new sequence contains two extra
disulfide bridges and is partially O-glycosylated at Thr596,
the glycosylated form representing about 50% of the
variant. These features make albumin KeÂnitra unique
among the genetic variants of HSA that have so far been
characterized. The low plasma concentration of the variant,
about 15% of the total albumin content, indicates that the
extensive modifications decrease its in vivo stability. In the
known three-dimensional structure of HSA [30], residues
575±583 correspond to the C-terminal part of helix
h10(III). Because of the strain imposed by the two new
disulfide bonds, a premature breakdown of this helix is
likely to occur in proximity of position 570 of the variant.
This is in agreement with secondary structure predictions
that suggest the presence of an additional helix encom-
passing residues 580±590 [31]. Because this new elongated
variant as well as all the known truncated alloalbumins are
present in serum at levels ranging from only 2±30%, any
major change from the native structure of the C-terminal
region of HSA appears to be crucial for the stability of the
protein.
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